BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 26381047)

  • 1. The interaction of genetic determinants in the outcome of HCV infection: evidence for discrete immunological pathways.
    Hydes TJ; Moesker B; Traherne JA; Ashraf S; Alexander GJ; Dimitrov BD; Woelk CH; Trowsdale J; Khakoo SI
    Tissue Antigens; 2015 Oct; 86(4):267-75. PubMed ID: 26381047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study.
    Suppiah V; Gaudieri S; Armstrong NJ; O'Connor KS; Berg T; Weltman M; Abate ML; Spengler U; Bassendine M; Dore GJ; Irving WL; Powell E; Hellard M; Riordan S; Matthews G; Sheridan D; Nattermann J; Smedile A; Müller T; Hammond E; Dunn D; Negro F; Bochud PY; Mallal S; Ahlenstiel G; Stewart GJ; George J; Booth DR;
    PLoS Med; 2011 Sep; 8(9):e1001092. PubMed ID: 21931540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A polymorphism in IL28B distinguishes exposed, uninfected individuals from spontaneous resolvers of HCV infection.
    Knapp S; Warshow U; Ho KM; Hegazy D; Little AM; Fowell A; Alexander G; Thursz M; Cramp M; Khakoo SI
    Gastroenterology; 2011 Jul; 141(1):320-5, 325.e1-2. PubMed ID: 21600205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of killer cell immunoglobulin-like receptors with spontaneous clearance of hepatitis C virus in the Chinese population.
    Shan Z; Huang J; Liao Q; Huang K; Wang M; Xu R; Tang X; Zhang W; Nelson K; Fu Y; Li C; Rong X
    Transfusion; 2018 Apr; 58(4):1028-1035. PubMed ID: 29446443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation.
    de Arias AE; Haworth SE; Belli LS; Burra P; Pinzello G; Vangeli M; Minola E; Guido M; Boccagni P; De Feo TM; Torelli R; Cardillo M; Scalamogna M; Poli F
    Liver Transpl; 2009 Apr; 15(4):390-9. PubMed ID: 19326408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KIR, HLA, and IL28B variant predict response to antiviral therapy in genotype 1 chronic hepatitis C patients in Japan.
    Nozawa Y; Umemura T; Joshita S; Katsuyama Y; Shibata S; Kimura T; Morita S; Komatsu M; Matsumoto A; Tanaka E; Ota M
    PLoS One; 2013; 8(12):e83381. PubMed ID: 24349500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection.
    Fitzmaurice K; Hurst J; Dring M; Rauch A; McLaren PJ; Günthard HF; Gardiner C; Klenerman P; ;
    Gut; 2015 May; 64(5):813-9. PubMed ID: 24996883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon lambda-3 is not associated with clinical outcome in patients with HCV-induced compensated cirrhosis: a long-term cohort study.
    Bruno S; Thompson AJ; Critelli R; Crosignani A; Rossi S; De Lisi S; Cariani E; Zermiani P; Vaira V; Boccaccio V; Maisonneuve P; Villa E
    Antiviral Res; 2015 Jan; 113():27-32. PubMed ID: 25446338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and histopathological changes in different KIR gene profiles in chronic HCV Romanian patients.
    Ursu LD; Calenic B; Diculescu M; Dima A; Stoian IT; Constantinescu I
    Int J Immunogenet; 2021 Feb; 48(1):16-24. PubMed ID: 32961633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection.
    Thanapirom K; Suksawatamnuay S; Sukeepaisarnjaroen W; Tangkijvanich P; Treeprasertsuk S; Thaimai P; Wasitthankasem R; Poovorawan Y; Komolmit P
    PLoS One; 2015; 10(9):e0137365. PubMed ID: 26339796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection.
    Vidal-Castiñeira JR; López-Vázquez A; Díaz-Peña R; Alonso-Arias R; Martínez-Borra J; Pérez R; Fernández-Suárez J; Melón S; Prieto J; Rodrigo L; López-Larrea C
    J Virol; 2010 Jan; 84(1):475-81. PubMed ID: 19846535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of human leukocyte antigen class I and II alleles on hepatitis C viral load among chronic hepatitis C patients in Southern Taiwan.
    Tseng KC; Tseng CW; Hsieh YH; Chang CK; Lai NS; Hung TH; Chang TT
    Hum Immunol; 2013 Aug; 74(8):978-82. PubMed ID: 23628398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the host genetics of chronic hepatitis B and C.
    Thursz M; Yee L; Khakoo S
    Semin Liver Dis; 2011 May; 31(2):115-27. PubMed ID: 21538279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clearance and persistence of hepatitis C virus in a Tunisian population: association with HLA class I and class II.
    Ksiaa L; Ayed-Jendoubi S; Sfar I; Gorgi Y; Najjar HA; Abdallah TB; Ayed K
    Viral Immunol; 2007; 20(2):312-9. PubMed ID: 17603847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection.
    Lin CY; Chen JY; Lin TN; Jeng WJ; Huang CH; Huang CW; Chang SW; Sheen IS
    PLoS One; 2011 Mar; 6(3):e18322. PubMed ID: 21479134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C.
    Umemura T; Ota M; Katsuyama Y; Wada S; Mori H; Maruyama A; Shibata S; Nozawa Y; Kimura T; Morita S; Joshita S; Komatsu M; Matsumoto A; Kamijo A; Kobayashi M; Takamatsu M; Yoshizawa K; Kiyosawa K; Tanaka E
    Hum Immunol; 2014 Aug; 75(8):822-6. PubMed ID: 24929144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA-B*15:02 is associated with anemia in patients with chronic hepatitis C treated with pegylated interferon-α and ribavirin.
    Tseng CW; Hsieh YH; Chang CK; Lai NS; Hung TH; Wu SF; Tseng KC
    Tissue Antigens; 2012 Nov; 80(5):424-30. PubMed ID: 22931407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA-B, HLA-C and KIR improve the predictive value of IFNL3 for Hepatitis C spontaneous clearance.
    Frias M; Rivero-Juárez A; Rodriguez-Cano D; Camacho Á; López-López P; Risalde MÁ; Manzanares-Martín B; Brieva T; Machuca I; Rivero A
    Sci Rep; 2018 Jan; 8(1):659. PubMed ID: 29330418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimpanzee susceptibility to hepatitis C virus infection correlates with presence of Pt-KIR3DS2 and Pt-KIR2DL9: paired activating and inhibitory natural killer cell receptors.
    Abi-Rached L; Guethlein LA; Norman PJ; Parham P
    Immunogenetics; 2015 Oct; 67(10):625-8. PubMed ID: 26260270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural killer cell receptor variants and chronic hepatitis B virus infection in the Vietnamese population.
    Auer ED; Tong HV; Amorim LM; Malheiros D; Hoan NX; Issler HC; Petzl-Erler ML; Beltrame MH; Boldt ABW; Toan NL; Song LH; Velavan TP; Augusto DG
    Int J Infect Dis; 2020 Jul; 96():541-547. PubMed ID: 32422377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.